European Journal of Molecular & Clinical Medicine

Abstract

In this review article, you can find a brief summary of the complicated relationship of age, hypertension, renin-angiotensin-aldosterone system (RAAS), infection with inflammation and serious acute coronavirus 2 syndrome (SARS-CoV2). In coorbid elderly patients, especially people with high blood pressure, diabetes, obesity and cardiovascular disease, Coronavirus Disease 2019 (COVID-19) is more common and more severe. The use of RAAS inhibitors in COVID-19 patients is concerned. There are questions. Some doctors have considered the need to avoid inhibition of RAAS in order to decrease the risk for SARS-CoV2 to enter lung cells following binding to angiotensin-converting enzyme 2 (ACE2) receptors. We have a different view of the need to proceed using RAAS inhibitors in COVID-19 patients1,2. Our article was based on elderly patients because of the marked mismatch of the depressed immune system and an intensified, inflaming, inflammatory response that makes the geriatric patient a good candidate for therapeutic strategies for inflammatory reaction modulation. COVID-19 is an infectious storm that begins and aggravates during the illness. Various therapeutic approaches, including antivirals, interferon, anti-interleukins, hydroxychloroquine, anti-inflammatory medications, immunoglobulins from returning patients and heparins, were tested during the COVID-19 Pandemic. Any of these therapies found not to be beneficial, or even to cause significant complications. On the basis of existing data, the path and outcome of COVID-19 might influence early regulation of inflammatory response by neprilysin inhibition and RAAS modulation